IRCT20250525065882N1 IRCT 2025-06-15 Tehran University of Medical Sciences Lacosamide in Migraine Evaluating the effect of Lacosamide treatment on the severity of headache attacks and CGRP-LI levels in people with migraine: A triple-blind randomized clinical trial 2025-06-21 anticipated 44 Complete https://irct.ir/trial/83864 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using a random number table, patients will be randomly assigned to intervention and control groups. The table consists of a large set of numbers generated without a specific pattern and organized into a structured format. To apply this method, the researcher first designates sequential numbers for different groups, such as 0-22 for the intervention group and 23-44 for the placebo group. The researcher then selects a starting number, proceeds in a predetermined direction, records the numbers, and allocates them accordingly to the designated groups, Blinding description: In this study, both the patients and the prescribing physician will remain unaware of the nature of the drug and placebo, as well as the randomization process. Additionally, the researcher and statistical consultant will serve as a third blinded arm and will be subject to blinding procedures. An external observer will be aware of the drug and placebo but will have no role in their allocation. The placebo will be identical to the drug in terms of size, color, volume, and packaging. The required placebo will be sourced from the pharmaceutical company Kondor Pharma. 3 migraine. Intervention 1: Intervention group: The intervention group will receive Lacosamide medication daily at a dose of 50 mg provided by Actover Company for a duration of three months. Intervention 2: Intervention group: The placebo group will receive the placebo for three months at the same dosage as the medication prescribed to the other group. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is At this stage, it will not be made publicly available. However, we are open to sharing it upon reasonable request, subject to appropriate institutional approvals and ethical considerations.